The Pharma Data

NOVEMBER 27, 2020

Vaccine development to cure coronavirus is at an all-time high after Pfizer and BioNTech announced they had success with a possible vaccine candidate. UK firm develops solution for identifying whether patients are actually infectious from a virus or not. Read on to for the full insight.

Virus 52

Virus Vaccine International Immune Response 52

The Pharma Data

JANUARY 4, 2021

” Britain to Try Mix-and-Match COVID-19 Vaccinations. If a second dose of the first COVID-19 vaccine isn’t available or the maker isn’t known, then another vaccine may be used, new British guidelines say, The New York Times reported Sunday. Britain has green-lighted vaccines from Pfizer and AstraZeneca.

Vaccine 52

Vaccine Virus Hospitals Production 52

Drug Target Review

JUNE 1, 2023

La Jolla Institute for Immunology (LJI), US, scientists demonstrated how antibodies obtained from a clinical study participant attach to the SARS-CoV-2 spike protein and neutralise the virus. In the new study, antibodies were obtained from a clinical studies volunteer who received two doses of the Moderna SARS-CoV-2 vaccine.

Virus 97

Virus Vaccine Immune Response Research 97

The Pharma Data

SEPTEMBER 30, 2021

As one among the leading global vaccines companies, we still bring options which help protect people’s health round the world,” said Michael Greenberg, MD, MPH, Medical Head, Sanofi Pasteur North America. “We 4,5 The CDC recommends a primary dose of the MenACWY vaccine at 11-12 years old and a second dose at 16 years old. In the U.S.,

Vaccine 52

Vaccine Research Virus Disease 52

The Pharma Data

JANUARY 14, 2021

The new variant has three previously unseen mutations that “are likely to make the virus more infectious, making it easier for the virus to pass from person to person,” according to a university news release, CBS News reported. © 2021 HealthDay. © 2021 HealthDay. Posted: January 2021. Source link.

Virus 52

Virus Vaccine Disease Research 52

The Pharma Data

MARCH 3, 2022

The FDA decision is informed by the results of the Phase 2b proof-of-concept study of RSVpreF (NCT04032093), a global, double-blinded, placebo-controlled study that assessed the safety and immunogenicity of RSVpreF in healthy pregnant women ages 18 through 49 years old, who were vaccinated between 28- and 36-weeks gestation, and their infants.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. How do the COVID-19 vaccines work? The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. ” Can the vaccines make you sick? MONDAY, Jan.

Vaccine 52

Vaccine Virus DNA Doctors 52

The Pharma Data

FEBRUARY 1, 2021

They spent about an hour at the Huanan Seafood Market, which was the site of an outbreak of the virus in December 2019, the Associated Press reported. Initially, experts suspected the new coronavirus came from wild animals sold at the market, but the site has been largely ruled out as a source of the virus. © 2021 HealthDay.

Vaccine 52

Vaccine Virus Marketing Compliance 52

The Pharma Data

JULY 28, 2021

There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., The seventh vaccine candidate is an inert protein subunit. and Troy Randall, Ph.D.,

Vaccine 52

Vaccine Virus Clinical Trials Science 52

The Pharma Data

JULY 8, 2021

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. Those who unfortunately got COVID-19 despite being vaccinated were still better off than those who didn’t.”

Vaccine 52

Vaccine Virus Nurses Hospitals 52

The Pharma Data

SEPTEMBER 5, 2021

AstraZeneca and the European Commission have reached an agreement that ends legal proceedings over the execution of the Advance Purchase Agreement for the delivery of the COVID-19 vaccine Vaxzevria (ChAdOx1-S [Recombinant]). Legal proceedings by the European Commission against AstraZeneca were initiated in Brussels on 21 April 2021.

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

The Pharma Data

JANUARY 21, 2021

22, 2021 — Everyone has heard the scary reports about the new, more infectious coronavirus variants that are circulating in countries around the world, but scientists aren’t pushing the panic button at this point. Because the new COVID-19 vaccines should still work on these viral interlopers. FRIDAY, Jan.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Codon

AUGUST 26, 2024

He also explains how they could be used to combat pandemics on “day zero,” well before vaccines are developed. After the outbreak ended, it took another three years for the first Ebola vaccine by Merck to be approved. Timelines for vaccine development are shrinking, but can it move even faster?

RNA 88

RNA Virus DNA Vaccine 88

The Pharma Data

NOVEMBER 23, 2020

As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. Food and Drug Administration (FDA) and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today. The prices for the vaccines are moving targets, dependent upon the amount ordered.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. Early tests showed the jab, developed by US biotechnology company Novavax, leads to high levels of virus-fighting antibodies being produced. The trial on 10,000 people will now see if the vaccine can prevent people getting ill.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

JANUARY 8, 2021

Moderna COVID-19 Vaccine Protection May Last Years, Company Claims. 8, 2021 — Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine may prevent infection for years, CBS News reported Thursday. © 2021 HealthDay. Posted: January 2021. Professional. FRIDAY, Jan. CBS News Article.

Vaccine 52

Vaccine Virus Disease 52

The Pharma Data

JUNE 26, 2021

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection. All current COVID-19 vaccines and antibody-based therapeutics were designed to disrupt this route into cells, which requires a receptor called ACE2. The study is published June 23 in Cell Reports.

Virus 52

Virus Cell Biology Vaccine Research 52

The Pharma Data

NOVEMBER 17, 2021

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months. 2) From the body of evidence in clinical trials and real-world data, the vaccine has been shown to have an acceptable safety profile.(3,4,5,6,7).

Vaccine 52

Vaccine Clinical Trials Virus Licensing 52

The Pharma Data

JANUARY 4, 2021

4, 2021 — If a second dose of the first COVID-19 vaccine is not available or the maker is not known, then another vaccine may be used, new British guidelines say, The New York Times reported Sunday. Britain has green-lighted vaccines from Pfizer and AstraZeneca. © 2021 HealthDay. Posted: January 2021.

Vaccine 52

Vaccine Virus Production Science 52

The Pharma Data

JANUARY 14, 2021

COVID-19 Vaccine Rollout Nears 1 Million Doses Per Day. 14, 2021 — One month after the United States began what has become a troubled rollout of a national COVID-19 vaccination campaign, the effort is finally gathering real steam. © 2021 HealthDay. Posted: January 2021. Professional. THURSDAY, Jan.

Vaccine 52

Vaccine Virus Research Disease 52

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community.

Immune Response 52

Immune Response Virus Disease Doctors 52

The Pharma Data

AUGUST 9, 2021

Research by Lancaster University scientists to create a COVID-19 vaccine which can be administered through the nose has taken a significant step forward. The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus.

Vaccine 52

Vaccine Virus Immune Response Disease 52

PLOS: DNA Science

MAY 16, 2024

Had we grown complacent in a world freed from a list of once-deadly infectious diseases, thanks largely to vaccines and other public health measures? A Novel Virus Appears In retrospect, everything unfolded with astonishing speed. Work on vaccines ensued too. COVID clearly caught us off guard.

Virus 97

Virus DNA RNA Laboratories 97

The Pharma Data

JANUARY 16, 2021

16, 2021 — President-elect Joe Biden described an ambitious national vaccination plan on Friday that will deliver coronavirus vaccines to far more people and invoke a wartime law to boost vaccine production. But those promises will only be achieved if there are vaccines available. SATURDAY, Jan.

Vaccine 52

Vaccine Nurses Virus Hospitals 52

The Pharma Data

JANUARY 25, 2021

Moderna COVID-19 Vaccine Effective Against British, South African Variants. 25, 2021 — Moderna says its COVID-19 vaccine remains effective against two worrisome new coronavirus variants from Britain and South Africa, but it is somewhat less effective against the South African variant. © 2021 HealthDay. Professional.

Vaccine 52

Vaccine Virus 52

The Pharma Data

APRIL 7, 2022

announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). NYSE: PFE) and ReViral Ltd.

Virus 52

Virus Vaccine Clinical Development Hospitals 52

The Pharma Data

JANUARY 13, 2021

COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2. 13, 2021 — A candidate vaccine, Ad26.COV2.S, 13, 2021 — A candidate vaccine, Ad26.COV2.S, “Our interim analysis indicates that vaccine candidate Ad26.COV2.S “Our interim analysis indicates that vaccine candidate Ad26.COV2.S

Vaccine 52

Vaccine Virus Trials Research 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

MARCH 25, 2021

European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure. About TAK-003. 4,5 Efficacy varied by serotype.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

JANUARY 8, 2021

8, 2021 — As Americans await their COVID-19 shot, a new study of a different vaccine shows the power of Facebook posts in fueling “anti-vax” resistance to immunization. The study included more than 10 years of public Facebook posts on the human papillomavirus (HPV) vaccine. 8 in the journal Vaccine.

Vaccine 52

Vaccine Doctors Virus Disease 52

The Pharma Data

JANUARY 11, 2021

Testing Therapies, Antivirals and Vaccines. By the end of January, Johnson & Johnson is expected to deliver preliminary trial results for its one-dose COVID-19 vaccine candidate. . One of the open questions about the various vaccines against COVID-19 has been how long the protection offered will last. Other Industry News.

Vaccine 52

Vaccine Clinical Trials Immune Response Trials 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. These epitopes could then be used in a vaccine to train T cells, providing protective immunity.

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. population. The samples were stored after the researchers measured the T cell response.

Virus 52

Virus Immune Response Vaccine Research 52

The Pharma Data

JANUARY 4, 2021

4, 2021 — As U.S. officials ramped up efforts to vaccinate more Americans, scientists around the world wrestled with whether it would make sense to delay the second doses everyone will need so more people can be vaccinated more quickly. Each vaccine would still be delivered in two doses given four weeks apart.

Vaccine 52

Vaccine Immune Response Virus Hospitals 52

The Pharma Data

JANUARY 11, 2021

11, 2021 — U.S. health officials raced to ramp up the delivery of COVID-19 vaccines across the country as both coronavirus case counts and death tallies continued to hit record highs. We need to hit the reset and adopt a new strategy in trying to get [vaccines] out to patients.” MONDAY, Jan.

Vaccine 52

Vaccine Virus Assisted Living Nurses 52